Novel triple‑positive markers identified in human non‑small cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics-Reference-Cited by-同舟云学术

Novel triple‑positive markers identified in human non‑small cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics

Published:2018-05-24 Issue: Volume: Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Satar Nazilah¹,Fakiruddin Kamal²,Lim Moon²,Mok Pooi³,Zakaria Norashikin¹,Fakharuzi Noor²,Abd Rahman Ahmad²,Zakaria Zubaidah²,Yahaya Badrul¹,Baharuddin Puteri²

Affiliation:

1. Regenerative Medicine Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, 13200 Penang, Malaysia

2. Stem Cell Laboratory, Haematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), 50588 Kuala Lumpur, Malaysia

3. Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting hyaluronan metabolism-related molecules associated with resistant tumor-initiating cells potentiates chemotherapy efficacy in lung cancer;Scientific Reports;2024-07-22

2. Establishment, culture and characterization of gemcitabine hydrochloride‐resistant human non‐small cell lung carcinoma cell line derived cancer stem cells;Cell Biochemistry and Function;2024-06

3. Bioinformatics approach combined with experimental verification reveals OAS3 gene implicated in paclitaxel resistance in head and neck cancer;Head & Neck;2024-05-16

4. Functional roles of microRNAs in vasculogenic mimicry and resistance to therapy in human cancers: an update;Expert Review of Clinical Immunology;2024-05-09

5. Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer;Advanced Therapeutics;2024-03-25